Lecanumab (LeqembiTM) FDA-approved for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD) – collectively called early AD R. Scott Turner
January 20th, 2023
R. Scott Turner A breakthrough, finally! Leqembi is the first disease-modifying treatment for individuals with MCI and mild AD with solid evidence of effectiveness. Thus, Leqembi (previously…